- Business Wire•3 days ago
InVivo Therapeutics Holdings Corp. today announced that Thomas Ulich, M.D., Chief Scientific Officer, will present at the annual Partnering Forum, part of the Cell & Gene Meeting on the Mesa, to be held October 5-7 in La Jolla, California.
- Business Wire•9 days agoInVivo Therapeutics Announces Late-Breaking Oral Presentation at the 2016 Congress of Neurological Surgeons Annual Meeting
InVivo Therapeutics Holdings Corp. today announced that Michael Fehlings, M.D., Ph.D., Director of the Spinal Program at the Krembil Neuroscience Centre of Toronto Western Hospital and a Professor of Neurosurgery at the University of Toronto, will give a late-breaking oral presentation titled “Clinical-Pathological Assessment of Severe Traumatic Acute Thoracic Spinal Cord Injury: Post-Durotomy/Myelotomy ...
- Business Wire•15 days agoInVivo Therapeutics Announces Oral Platform Presentation at 2016 Congress of Neurological Surgeons Annual Meeting
InVivo Therapeutics Holdings Corp. today announced that Nicholas Theodore, M.D., Director of the John Hopkins Neurosurgical Spine Center, will be giving an oral platform presentation titled “High AIS Grade Conversion Rate Following Neuro-Spinal Scaffold Implantation in Acute Thoracic Complete AIS A Spinal Cord Injury : Potential Mechanisms” at the 2016 Congress of Neurological Surgeons Annual Meeting ...
InVivo Therapeutics Holdings Corp. (NVIV)
NasdaqGM - NasdaqGM Real Time Price. Currency in USD
|Ask||9.55 x 100|
|Day's Range||6.73 - 6.97|
|52wk Range||3.50 - 11.80|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-10.53|
|Avg Vol (3m)||213,668|
|Dividend & Yield||N/A (N/A)|